FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.
The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.
FibroBiologics, Inc. (FBLG) reports that stockholders approved, for purposes of Nasdaq Listing Rule 5635(d), the potential issuance of up to 8,163,266 shares of common stock upon exercise of warrants issued under a June 25, 2026 Securities Purchase Agreement and up to 285,714 shares upon exercise of additional warrants issued under an engagement letter with H.C. Wainwright & Co., LLC. At the September 17, 2026 Special Meeting, 3,431,761 votes were represented out of 8,283,193 entitled votes, and the proposal passed with 3,153,098 for, 258,217 against, and 20,446 abstentions.
The company also closed a $0.5 million private placement on September 15, 2026 with Chief Scientific Officer Hamid Khoja, Ph.D., involving 298,508 shares of common stock and accompanying warrants to purchase up to 298,508 shares. Each share-and-warrant unit was sold at $1.675, reflecting a common share value of $1.55 plus $0.125 per warrant. The warrants are immediately exercisable at $1.55 per share and expire five years from issuance, with net proceeds intended for general corporate purposes and working capital.
FibroBiologics, Inc. (FBLG) entered into a private placement with its Chief Scientific Officer, Hamid Khoja, on September 15, 2026, under which he purchased 298,508 shares of common stock together with warrants to purchase up to 298,508 additional shares. The securities were sold at an offering price of $1.675 per share and accompanying warrant, for gross proceeds of approximately $0.5 million. The warrants are exercisable at any time at an exercise price of $1.55 per share and expire five years from issuance, with standard anti-dilution adjustments. Following this transaction, Dr. Khoja beneficially owns 630,009 shares of FibroBiologics common stock (including common shares, warrant shares and vested options), representing about 7.5% of the outstanding common stock.
FibroBiologics, Inc. (FBLG) reported that Chief Scientific Officer Hamid Khoja acquired 298,508 shares of common stock on September 15, 2026 at $1.675 per share in a private placement, together with warrants to purchase up to 298,508 additional shares at an exercise price of $1.55 per share, exercisable until September 15, 2031. Following these awards, he holds 301,571 shares of common stock directly, along with 298,508 warrants.
FibroBiologics, Inc. (FBLG), a Delaware biotechnology company, filed a Form D for a new exempt private offering under Rule 506(b) of Regulation D. The company reports that it has sold $500,001 of securities in this offering, with no remaining amount available to be sold.
The securities consist of 298,508 shares of common stock and accompanying warrants exercisable at $1.55 per share for up to an additional 298,508 shares of common stock. The issuer states it intends to use the net proceeds for working capital and general corporate purposes, and reports no finders’ fees paid.
FibroBiologics, Inc. (FBLG) entered into a securities purchase agreement on September 15, 2026 with its Chief Scientific Officer, Hamid Khoja, Ph.D., for a private placement of 298,508 shares of common stock and accompanying warrants to purchase up to 298,508 additional shares.
The securities are priced at $1.675 per share and accompanying warrant, reflecting a $1.55 consolidated closing bid price on September 14, 2026 plus $0.125 per warrant, for expected gross proceeds of approximately $0.5 million before expenses. The warrants are immediately exercisable at $1.55 per share, have a five-year term, include cashless exercise features and standard anti-dilution adjustments, and may result in up to an additional 298,508 shares being issued. The transaction relies on Section 4(a)(2) and Rule 506(b) exemptions and is intended for general corporate purposes and working capital.
FibroBiologics, Inc. (symbol FBLG) filed an initial statement of beneficial ownership on Form 3 for Leigh Steinberg. Steinberg is identified as a director of the company and is not listed as an officer or a ten percent owner. The filing also references an Exhibit 24 Power of Attorney.
FibroBiologics, Inc. (FBLG), a clinical-stage biotechnology company focused on fibroblast-based therapeutics, reported that its Board appointed Leigh Steinberg as a Class II director effective August 20, 2026, with a term running until the 2028 annual meeting of stockholders. He will receive compensation consistent with other non-employee directors under the company’s Non-Employee Director Compensation Policy and has entered into FibroBiologics’ standard indemnification agreement. The company states that Mr. Steinberg has no related-party transactions requiring disclosure and was not appointed pursuant to any arrangements with other persons. A press release furnished as an exhibit highlights his five decades of sports agency experience, his advocacy for human longevity and brain health, and FibroBiologics’ portfolio of more than 270 patents issued and pending.
FibroBiologics, Inc. has a significant shareholder group reporting passive ownership. Armistice Capital, LLC and Steven Boyd, as joint reporting persons, report beneficial ownership of 738,977 shares of FibroBiologics common stock, representing 9.99% of the class.
The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager with shared voting and dispositive power over all 738,977 shares. The Master Fund has the economic right to receive dividends and sale proceeds, while Armistice Capital and Mr. Boyd may be deemed to share voting and investment power under an Investment Management Agreement.
FibroBiologics, Inc. is a clinical-stage cell-therapy company developing fibroblast-based treatments for chronic diseases. For the three and six months ended June 30, 2026, it reported net losses of $4,117 thousand and $9,117 thousand, driven by research and development expenses of $1,658 thousand and $4,611 thousand and general, administrative and other expenses of $2,375 thousand and $4,490 thousand, respectively.
Cash and cash equivalents were $3,515 thousand and total assets $7,929 thousand as of June 30, 2026, with net cash used in operating activities of $7,655 thousand in the first half. The company raised capital through a March SEPA draw, an April registered offering (including common stock and pre-funded warrants), an at-the-market program, and a June private placement of $3,000 thousand of pre-funded warrants plus accompanying warrants, contributing to additional paid-in capital of $67,916 thousand. Management states that its cash balance, continued losses and lack of revenue raise substantial doubt about its ability to continue as a going concern.
The pipeline advanced with a Phase 1/2 diabetic foot ulcer trial of CYWC628 in Australia, though enrollment is slower than planned; interim six-week data are expected after a defined number of patients per arm complete treatment. The company also discloses a Nasdaq Staff Determination to delist its securities for bid-price noncompliance and has requested a hearing, which temporarily stays delisting while it seeks to regain compliance.
FibroBiologics, Inc. is calling a virtual special meeting on September 17, 2026 to seek stockholder approval, under Nasdaq Listing Rule 5635(d), for the potential issuance of up to 8,163,266 shares of common stock upon exercise of outstanding Warrants under a June 25, 2026 securities purchase agreement and up to 285,714 shares upon exercise of Placement Agent Warrants.
These Warrants carry exercise prices of $0.735 and $0.9188 per share; if fully exercised they would yield approximately $6.0 million and $263 thousand in gross proceeds, respectively, but would dilute existing holders through new common shares.
As of July 20, 2026 there were 6,658,193 common shares outstanding and 125 super-voting Series C Preferred shares, each with 13,000 votes. The Board holds an irrevocable proxy over these preferred shares and plans to cast 1,625,000 votes, about 20% of eligible votes, in favor of the proposal. If approval is not obtained, the company states it cannot issue shares above Nasdaq’s 20% threshold under these Warrants and may owe liquidated damages, potentially straining liquidity and requiring emergency financing, while repeated stockholder meetings every 90 days would add legal cost and management distraction.